



Celgene Corporation  
Investor Relations Department  
86 Morris Avenue  
Summit, NJ 07901  
United States

[Visit IR website](#)   
[Sign-up for e-mail alerts](#)

#### NASDAQ: CELG

Last Trade: 131.26

Trade Time: 4:00 PM ET  
Aug 16, 2017

Change: -0.11   
(0.084%)

Day Range 130.38 - 132.12

52-Week  
Range 96.93 - 139.00

Volume 2,219,882

Stock information is provided by eSignal,  
stock charts provided by EDGAR Online.  
Stock data is delayed approximately 20  
minutes.

## Company Profile

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of innovative therapies for the treatment of cancer and immune-inflammatory related diseases. Our portfolio of commercial products include REVLIMID®, VIDAZA®, THALOMID®, POMALYST®/IMNOVID®, ABRAXANE®, OTEZLA®, ISTODAX® and IDHIFA®. The drug candidates in our pipeline are at various stages of preclinical and clinical development. These cand... [\(more\)](#)

## Stock Performance



## Press Releases [\[ View all \]](#)

*Aug 1, 2017*  
[FDA Grants Approval of IDHIFA®. the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation](#)

*Jul 28, 2017*  
[Celgene Corporation to Webcast at Upcoming Investor Conference](#)

*Jul 27, 2017*  
[Celgene Reports Second Quarter 2017 Operating and Financial Results](#)

*Jul 25, 2017*  
[Celgene Corporation Announces Settlement of Civil Litigation](#)

*Jul 5, 2017*  
[Celgene Corporation Enters Into Global Strategic Immuno-Oncology Collaboration with BeiGene to Advance PD-1 Inhibitor Program for Solid Tumor Cancers](#)

## Financials [\[ View all \]](#)

*Feb 10, 2017*  
[Annual Report \(10-K\)](#)

*Apr 27, 2017*  
[Proxy Statement \(DEF 14A\)](#)

*Jul 27, 2017*  
[Quarterly Report \(10-Q\)](#)

*Apr 27, 2017*  
[Quarterly Report \(10-Q\)](#)

*Oct 27, 2016*  
[Quarterly Report \(10-Q\)](#)